ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1046

Risk Factors Associated with Interstitial Lung Disease in Patients with RA: Findings from a Retrospective Healthcare Database Analysis

Joe Zhuo1, Qisu Zhang2, Keith Knapp3, Yuexi Wang4, Cynthia Gutierrez4, Ding He4, Lin Xie4, Sonie Lama1 and Gary Craig5, 1Bristol-Myers Squibb Company, Princeton, NJ, 2STATinMED Research (at time of analysis), Ann Arbor, MI, 3Discus Analytics LLC, Spokane, WA, 4STATinMED Research, Ann Arbor, MI, 5Arthritis Northwest, PLLC, Spokane, WA

Meeting: ACR Convergence 2020

Keywords: Diagnostic criteria, interstitial lung disease, rheumatoid arthritis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of RA and is associated with increased morbidity and mortality.1 Previous studies have shown variability in risk factors for RA-associated ILD (RA-ILD).1,2 The objective of this analysis was to systematically evaluate the risk factors of RA-ILD in a real-world population of patients with RA.

Methods: Patient demographic and disease characteristics were retrospectively analyzed following data extraction from the Discus Analytics JointMan database, a large US electronic medical records-based dataset. Adults with an RA diagnosis (International Classification of Disease, Ninth Revision, Clinical Modification [ICD-9-CM] code: 714.0; ICD, Tenth Revision, CM [ICD-10-CM] codes: M05, M06) between January 1, 2009 and September 20, 2019, ≥1 visit after the initial visit date, no diagnosis code for ILD prior to RA diagnosis and no diagnosis code for drug-induced ILD at any time during the study period were included in the analysis. Patients with ILD were identified by ICD diagnosis codes (ICD-9-CM codes: 516.0, 516.2, 516.3, 516.4, 516.5, 516.8, 516.9; ICD-10-CM codes: J84.0, J84.1, J84.2, J84.81, J84.82, J84.83, J84.89, J84.9) or by provider indication. Potential predictors of RA-ILD were analyzed by Cox regression model. Patient demographic and co-morbid conditions were collected at baseline (defined as 6 months prior to or on date of initial RA diagnosis). RA characteristics were identified during and after the initial RA diagnosis and were controlled as time-varying covariates in the Cox model. Significance was set at p< 0.05.

Results: Of the 5817 patients included, 5612 had RA only and 205 had RA-ILD. Several baseline differences between patients with and without ILD were identified: a greater proportion of patients with RA-ILD vs RA only were older, male, of white race, had a history of chronic obstructive pulmonary disease (COPD) and had more severe and more active RA than did patients with RA only (Table 1).3 Cox multivariate regression analysis showed older age ( >65 years old) and a history of COPD at baseline to be risk factors for developing ILD (Figure 1). Additionally, several time-varying covariates (anti-CCP positivity, CRP >5 mg/L and a moderate-to-high CDAI score) were also shown to be predictive of developing ILD.

Conclusion: In this large, real-world analysis of patients with RA, several risk factors for RA-ILD were identified: age, COPD, anti-CCP+, CRP and CDAI score. Recognition of these risk factors may lead to improved identification and a tailored approach to treatment of RA-ILD.

References:

  1. Spagnolo P, et al. Arthritis Rheumatol 2018;70:1544–1554.
  2. Kiely P, et al. BMJ Open 2019:9:e028466.
  3. Zhuo J, et al. Ann Rheum Dis 2020;79:24-25 (abstract OP0035).

Medical writing: Rachel Rankin (Caudex).


Disclosure: J. Zhuo, Bristol-Myers Squibb Company, 1, 3; Q. Zhang, STATinMED Research, 3; K. Knapp, Bristol-Myers Squibb Company, 5, Discus Analytics, 3; Y. Wang, STATinMED Research, 3; C. Gutierrez, None; D. He, Bristol-Myers Squibb Company, 5, 9; L. Xie, None; S. Lama, Bristol-Myers Squibb Company, 3, 4; G. Craig, Arthritis Northwest, 1, Discus Analytics, 1, Bristol-Myers Squibb, 1, 2, 3, Gilead, 1, MR, 1, Novartis, 5, 8, Pfizer, 1, Amgen/Celgene, 1, Eli Lilly, 1, Genentech, 1, 2, Sanofi, 1, UCB, 1, AbbVie, 1.

To cite this abstract in AMA style:

Zhuo J, Zhang Q, Knapp K, Wang Y, Gutierrez C, He D, Xie L, Lama S, Craig G. Risk Factors Associated with Interstitial Lung Disease in Patients with RA: Findings from a Retrospective Healthcare Database Analysis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/risk-factors-associated-with-interstitial-lung-disease-in-patients-with-ra-findings-from-a-retrospective-healthcare-database-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-associated-with-interstitial-lung-disease-in-patients-with-ra-findings-from-a-retrospective-healthcare-database-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology